Desmopressin Monotherapy for Monosymptomatic Nocturnal Enuresis

Launched by AL-AZHAR UNIVERSITY · Feb 28, 2024

Keywords

ClinConnect Summary

This clinical trial is studying the use of desmopressin, a medication, to help children aged 7 to 14 who experience monosymptomatic nocturnal enuresis, which is a medical term for bedwetting. Bedwetting can be distressing for both children and their families, affecting social life and self-esteem. In this study, researchers aim to understand how effective desmopressin is for treating this common condition, particularly in children who do not have other bladder issues during the day.

To participate, children must be between 7 and 14 years old and have primary monosymptomatic nocturnal enuresis. However, those with other medical conditions like urinary tract infections, diabetes, or certain neurological and psychological disorders will not be eligible. Participants can expect to receive guidance on their condition and treatment options, and they will be part of a supportive environment aimed at improving their well-being. Overall, this trial seeks to find effective solutions for a condition that affects many families.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • School age group (from 7 to 14 years)
• • Primary monosymptomatic nocturnal enuresis
• Exclusion Criteria:
• • Patients with one or more of the following will be excluded from the study.
• • Diurnal enuresis
• • Urinary tract infection within the preceding 3 months
• • Diabetes mellitus
• • History of renal disease, hypertension or genitourinary abnormality, neurological disease, or psychological disease.
• • Post-micturition residual urine \>1/3 expected bladder capacity.
• • Each patient will be subjected to the following.